RESUMEN
Firsocostat (FIR: previously GS-0976), a highly sensitive OATP substrate, reduces hepatic de novo lipogenesis (DNL) by inhibiting acetyl-CoA carboxylases (ACC). Measuring the pharmacodynamic (PD) efficacy of FIR on DNL provides a unique opportunity to determine optimal dosing strategies for liver-targeted OATP substrates in settings of altered OATP function. A randomized, four-way crossover drug-drug interaction study was conducted. Hepatic DNL, a marker for ACC activity, was measured in 28 healthy volunteers after reference, single dose FIR 10 mg, FIR 10 mg plus the OATP inhibitor rifampin (RIF) 300 mg i.v., or RIF 300 mg i.v. (control for DNL effect of RIF), each separated by a 7-day washout. Samples were collected for pharmacokinetic (PK) and PD assessments through 24 hours after each treatment. Hepatic DNL and its inhibition by FIR were assessed. Twenty-four subjects completed the study. All adverse events were mild. RIF alone increased hepatic DNL area under the effect curve from time of administration up to the time of the last quantifiable concentration (AUEClast ; 35.7%). Despite a 5.2-fold increase in FIR plasma exposure (area under the concentration-time curve from zero to infinity (AUCinf )) when administered with RIF, FIR alone, and FIR + RIF had the same hepatic PD effect, 37.1% and 34.9% reduction in DNL AUEClast , respectively, compared with their respective controls. These findings indicate that large decreases in OATP activity do not alter hepatic intracellular exposure (as inferred by no change in PD) for drugs that are primarily eliminated hepatically and permeability rate-limited, such as FIR. These results support PK theory that has been difficult to test and provide practical guidance on administration of liver-targeted drugs in settings of reduced OATP function.
Asunto(s)
Isobutiratos/farmacocinética , Hígado/efectos de los fármacos , Transportadores de Anión Orgánico/antagonistas & inhibidores , Oxazoles/farmacocinética , Pirimidinas/farmacocinética , Adulto , Interacciones Farmacológicas , Femenino , Humanos , Isobutiratos/administración & dosificación , Isobutiratos/efectos adversos , Isobutiratos/sangre , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Oxazoles/administración & dosificación , Oxazoles/efectos adversos , Oxazoles/sangre , Pirimidinas/administración & dosificación , Pirimidinas/efectos adversos , Pirimidinas/sangre , Rifampin/farmacologíaRESUMEN
RATIONALE: Proxalutamide is a novel drug for the treatment of prostate cancer. However, to date, there are almost no reports on the pharmacokinetics of proxalutamide in vivo. This study developed a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method to determine the concentrations of proxalutamide in biological samples for pharmacokinetic studies. METHODS: Chromatographic separation was achieved on a Kromasil 100-5C8 column followed by gradient elution using a Shimadzu HPLC system. MS was performed in positive ion electrospray ionization mode using a SCIEX API 4000 triple quadrupole system. A simple and rapid one-step protein precipitation method was used for sample processing, and a low sample volume of 10 µL was used for processing and analysis. RESULTS: The method was validated to show good selectivity, sensitivity, precision, and accuracy. Good linearity (r2 > 0.99) was observed for rat plasma (range: 2-5000 ng/mL) and rat tissue homogenates (range: 2-2000 ng/mL). The extraction recovery was above 98%, and no significant matrix effect was observed. This method was successfully applied to investigate the pharmacokinetics and tissue distribution of proxalutamide in rats. CONCLUSIONS: A rapid and sensitive LC/MS/MS method was developed and validated to determine the quantity of proxalutamide in rat plasma and tissue homogenates and to further study the pharmacokinetic parameters of proxalutamide in a rat model. The results showed that proxalutamide had good oral bioavailability and wide tissue distribution in vivo.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Oxazoles/farmacocinética , Plasma/química , Neoplasias de la Próstata/tratamiento farmacológico , Espectrometría de Masas en Tándem/métodos , Tiohidantoínas/farmacocinética , Estructuras Animales/química , Estructuras Animales/metabolismo , Animales , Disponibilidad Biológica , Humanos , Masculino , Oxazoles/administración & dosificación , Oxazoles/sangre , Neoplasias de la Próstata/sangre , Ratas , Ratas Sprague-Dawley , Tiohidantoínas/administración & dosificación , Tiohidantoínas/sangre , Distribución TisularRESUMEN
The objective of this phase 1 study was to evaluate the pharmacokinetics, safety, and tolerability of baricitinib after single and multiple doses in healthy Chinese adults. Eligible subjects received a once-daily dose of baricitinib 2, 4, or 10 mg or placebo on day 1 (single dose) and days 4 through 10 for 7 consecutive days (multiple doses). Plasma pharmacokinetic samples were collected up to 48 hours after dosing on days 1 and 10, with predose samples collected before dosing on day 1 and days 4 through 10. Safety and tolerability were also assessed. Baricitinib was rapidly absorbed, reaching peak plasma concentrations within 0.5 to 1 hour (median). Plasma concentrations declined rapidly following the attainment of peak concentrations, with a mean terminal half-life of 5.7 to 7.3 hours. Steady-state plasma concentrations of baricitinib were achieved after the second day of once-daily dosing, with minimal accumulation of baricitinib in plasma (up to 10% increase in area under the plasma concentration-time curve). Single- and multiple-dose mean values for area under the plasma concentration-time curve from time zero to infinity and maximum plasma concentration appeared to increase in an approximately dose-proportional manner across the dose range. Single and multiple oral doses of once-daily baricitinib up to 10 mg were well tolerated by healthy Chinese subjects.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Azetidinas/farmacocinética , Voluntarios Sanos/estadística & datos numéricos , Oxazoles/farmacocinética , Purinas/farmacocinética , Pirazoles/farmacocinética , Sulfonamidas/farmacocinética , Administración Oral , Adulto , Área Bajo la Curva , Pueblo Asiatico/etnología , Azetidinas/administración & dosificación , Azetidinas/sangre , Estudios de Casos y Controles , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Tolerancia a Medicamentos , Femenino , Semivida , Humanos , Masculino , Persona de Mediana Edad , Oxazoles/administración & dosificación , Oxazoles/sangre , Placebos/administración & dosificación , Purinas/administración & dosificación , Purinas/sangre , Pirazoles/administración & dosificación , Pirazoles/sangre , Seguridad , Sulfonamidas/administración & dosificación , Sulfonamidas/sangreRESUMEN
An innovative open-label, crossover clinical study was used to investigate the excretion balance, pharmacokinetics, and metabolism of nemiralisib-an inhaled phosphoinositide 3-kinase delta inhibitor being developed for respiratory diseases. Six healthy men received a single intravenous microtracer of 10 µg [14C]nemiralisib with a concomitant inhaled nonradiolabeled 1000 µg dose followed by an oral 800 µg dose of [14C]nemiralisib 14 days later. Complementary methods including accelerator mass spectrometry allowed characterization of a range of parameters including oral absorption (Fabs), proportion of nemiralisib escaping gut wall metabolism (Fg), hepatic extraction (Eh), fraction of dose absorbed from inhaled dose (Flung), and renal clearance. Intravenous pharmacokinetics of nemiralisib were characterized by low blood clearance (10.0 l/h), long terminal half-life (55 hours), and high volume of distribution at steady state (728 l). Nemiralisib exhibited moderate inhaled and oral bioavailability (38% and 35%) while Flung was 29%. Absorption and first-pass parameters were corrected for blood renal clearance and compared with values without correction. Any swallowed nemiralisib was relatively well absorbed (Fabs, 0.48) with a high fraction escaping gut wall metabolism and low extraction by the liver (Fg and Eh being 0.83 and 0.10, respectively). There were no major human plasma metabolites requiring further qualification in animal studies. Both unchanged nemiralisib and its oxidative/conjugative metabolites were secreted in bile, with nemiralisib likely subject to further metabolism through enterohepatic recirculation. Direct renal clearance and metabolism followed by renal clearance were lesser routes of elimination. SIGNIFICANCE STATEMENT: A number of innovative features have been combined into one small clinical study enabling a comprehensive description of the human pharmacokinetics and metabolism of an inhaled molecule. Design elements included an intravenous 14C tracer administration concomitant with an inhalation dose that enabled derivation of parameters such as fraction absorbed (Fabs), the proportion of drug escaping first-pass extraction through the gut wall and liver (Fg and Fh) and hepatic extraction (Eh). Entero-test bile sampling enabled characterization of biliary elimination pathways.
Asunto(s)
Monitoreo de Drogas/métodos , Indazoles/farmacocinética , Indoles/farmacocinética , Oxazoles/farmacocinética , Piperazinas/farmacocinética , Inhibidores de Proteínas Quinasas/farmacocinética , Administración por Inhalación , Administración Intravenosa , Administración Oral , Adulto , Disponibilidad Biológica , Radioisótopos de Carbono , Estudios Cruzados , Heces/química , Voluntarios Sanos , Humanos , Indazoles/administración & dosificación , Indazoles/sangre , Indazoles/orina , Indoles/administración & dosificación , Indoles/sangre , Indoles/orina , Inyecciones Intravenosas , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Oxazoles/administración & dosificación , Oxazoles/sangre , Oxazoles/orina , Piperazinas/administración & dosificación , Piperazinas/sangre , Piperazinas/orina , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/sangre , Inhibidores de Proteínas Quinasas/orina , Distribución TisularRESUMEN
Aim: To develop a bioanalytical method to support pharmacokinetic evaluation of DNDI-VL-2098 in mouse, rat, dog and hamster following oral administration. Results & methodology: A robust LC-MS/MS bioanalytical method was developed to quantify DNDI-VL-2098. DNDI-VL-2098 showed time-dependent recovery loss in acetonitrile precipitated plasma in all species. Acid-lysed whole blood was identified as a matrix in which recovery was stable over time. A two-step extraction procedure was used, with protein precipitation followed by liquid-liquid extraction with methyl tert-butyl ether. The assay was validated in the dynamic range of 5-5000 ng/ml for mouse, rat and dog blood, and a fit-for-purpose method was developed for hamster. Conclusion: A specific LC-MS/MS assay for DNDI-VL-2098 was developed and validated in hemolyzed blood.
Asunto(s)
Análisis Químico de la Sangre/métodos , Cromatografía Liquida/métodos , Nitroimidazoles/sangre , Oxazoles/sangre , Espectrometría de Masas en Tándem/métodos , Métodos Analíticos de la Preparación de la Muestra , Animales , Cricetinae , Marcaje Isotópico , Ratones , RatasRESUMEN
PURPOSE: Nemiralisib, a phosphoinositide 3-kinase δ inhibitor, is being investigated as an immunomodulatory agent with anti-inflammatory properties in chronic obstructive pulmonary disease. This study evaluated the pharmacokinetic (PK) properties and safety of a new formulation of nemiralisib that contains 0.4% magnesium stearate. METHODS: In this randomized, double-blind, parallel-group study, healthy individuals received a single dose of 500 or 750 µg of nemiralisib administered via the Ellipta dry powder inhaler (DPI) (n = 6 in each treatment group). Aerodynamic particle size distribution (APSD) data comparing previous and new formulations were available before the study. Serial PK analyses for plasma exposure and safety assessments were performed during the first 24 h after dosing, with follow-up measurements on days 3 and 6 in clinic. FINDINGS: APSD had increases of approximately 6-fold and 2-fold in very fine particle mass and fine particle mass over the previous (Diskus) formulation. In humans, systemic exposure (AUC) was greater after inhalation of 750 versus 500 µg of nemiralisib (AUC0-t: 17,200 hâpg/mL; 95% CI, 10,900-27,200 hâpg/mL and 13,100; 95% CI, 8130-21,000 hâpg/mL, respectively). A low frequency of individual adverse events and no serious adverse events were reported after both doses. IMPLICATIONS: After single-dose inhalation of 500 and 750 µg of nemiralisib from the Ellipta DPI in healthy individuals, plasma PK data were well defined, and as predicted based on previous PK and APSD data, exposure was increased with the new formulation. Nemiralisib was well tolerated with no new safety issues identified. These data supported progression of nemiralisib to a Phase IIb study in patients with chronic obstructive pulmonary disease. ClinicalTrials.gov identifier: NCT03189589.
Asunto(s)
Inhaladores de Polvo Seco , Indazoles , Indoles , Oxazoles , Piperazinas , Administración por Inhalación , Método Doble Ciego , Humanos , Indazoles/administración & dosificación , Indazoles/efectos adversos , Indazoles/sangre , Indazoles/farmacocinética , Indoles/administración & dosificación , Indoles/efectos adversos , Indoles/sangre , Indoles/farmacocinética , Oxazoles/administración & dosificación , Oxazoles/efectos adversos , Oxazoles/sangre , Oxazoles/farmacocinética , Piperazinas/administración & dosificación , Piperazinas/efectos adversos , Piperazinas/sangre , Piperazinas/farmacocinéticaRESUMEN
Nemiralisib (GSK2269557), a potent inhaled inhibitor of phosphoinositide 3-kinase δ (PI3Kδ), is being developed for the treatment of respiratory disorders including chronic obstructive pulmonary disease. Determining the pharmacokinetic (PK) and pharmacodynamic (PD) responses of inhaled drugs early during drug development is key to informing the appropriate dose and preferred dose regimen in patients. We set out to measure PD changes in induced sputum in combination with drug concentrations in plasma and bronchoalveolar lavage (BAL) taken from healthy smokers (n = 56) treated for up to 14 days with increasing doses of inhaled nemiralisib (0.1-6.4 mg). Induced sputum analysis demonstrated a dose-dependent reduction in phosphatidylinositol-(4,5)-trisphosphate (PIP3, the product of PI3K activation), with a maximum placebo-corrected reduction of 23% (90% confidence interval [CI], 11%-34%) and 36% (90% CI, 11%-64%) after a single dose or after 14 days of treatment with nemiralisib, respectively (2 mg, once daily). Plasma analysis suggested a linear PK relationship with an observed accumulation of â¼3- to 4.5-fold (peak vs. trough) in plasma exposure after 14 days of nemiralisib treatment. The BAL analysis at trough confirmed higher levels of the drug in the lungs versus plasma (32-fold in the BAL fluid component, and 214-fold in the BAL cellular fraction). A comparison of the drug levels in plasma and the reductions in sputum PIP3 showed a direct relationship between exposure and PIP3 reduction. These results demonstrated target engagement upon treatment with inhaled nemiralisib and provide confidence for a once-daily dosing regimen.
Asunto(s)
Voluntarios Sanos , Indazoles/farmacología , Indazoles/farmacocinética , Indoles/farmacología , Indoles/farmacocinética , Oxazoles/farmacología , Oxazoles/farmacocinética , Inhibidores de las Quinasa Fosfoinosítidos-3/farmacología , Inhibidores de las Quinasa Fosfoinosítidos-3/farmacocinética , Piperazinas/farmacología , Piperazinas/farmacocinética , Fumadores , Adulto , Líquido del Lavado Bronquioalveolar/química , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Indazoles/sangre , Indoles/sangre , Masculino , Persona de Mediana Edad , Oxazoles/sangre , Fosfatidilinositoles/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3/sangre , Piperazinas/sangre , Esputo/efectos de los fármacos , Esputo/metabolismoRESUMEN
Colloidal drug aggregates have been a nuisance in drug screening, yet, because they inherently comprise drug-rich particles, they may be useful in vivo if issues of stability can be addressed. As the first step toward answering this question, we optimized colloidal drug aggregate formulations using a fluorescence-based assay to study fulvestrant colloidal formation and stability in high (90%) serum conditions in vitro. We show, for the first time, that the critical aggregation concentration of fulvestrant depends on media composition and increases with serum concentration. Excipients, such as polysorbate 80, stabilize fulvestrant colloids in 90% serum in vitro for over 48 h. Using fulvestrant and an investigational pro-drug, pentyloxycarbonyl-( p-aminobenzyl) doxazolidinylcarbamate (PPD), as proof-of-concept colloidal formulations, we demonstrate that the in vivo plasma half-life for stabilized colloids is greater than their respective monomeric forms. These studies demonstrate the potential of turning the nuisance of colloidal drug aggregation into an opportunity for drug-rich formulations.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacocinética , Carbamatos/química , Carbamatos/farmacocinética , Doxorrubicina/análogos & derivados , Oxazoles/química , Oxazoles/farmacocinética , Profármacos/química , Profármacos/farmacocinética , Animales , Antineoplásicos/sangre , Carbamatos/sangre , Coloides , Doxorrubicina/sangre , Doxorrubicina/química , Doxorrubicina/farmacocinética , Estabilidad de Medicamentos , Excipientes , Femenino , Fulvestrant/química , Humanos , Células MCF-7 , Ratones , Trasplante de Neoplasias , Oxazoles/sangre , Polisorbatos/química , Prueba de Estudio Conceptual , SueroRESUMEN
The aim of the study was to assess the safety, tolerability, and pharmacokinetics of single and repeat doses of nemiralisib administered via a dry powder inhaler to healthy Japanese subjects. This was a single-center, double-blind, randomized, placebo-controlled, parallel, single- and repeat-ascending-dose study. Thirty-six healthy Japanese male subjects were randomized to receive either 1 dose strength of nemiralisib or placebo. The study consisted of a screening period, a single-dose session (session 1), a repeat-dose session (session 2), a 10-day washout period between the sessions, and then a follow-up visit 10 ± 1 days after the last dose of session 2. No serious adverse events were reported. No clinically significant abnormalities were found in clinical laboratory results, vital signs, or spirometry results. Generally, exposure (maximum observed plasma concentration [Cmax ] and area under the concentration-time curve [AUC]) increased with dose in an approximately proportional manner. Plasma Tmax was achieved rapidly at approximately 0.08 hours, and the terminal elimination half-life (T1/2 ) was approximately 40 hours. Tmax and T1/2 did not change between days or doses in the single- and repeat-dose sessions. Following 10 daily doses of 200, 500, and 700 µg nemiralisib, accumulation was observed, and the ratios (session 2, day 10:session 1) for Ro(AUC0-24 ) and R(Cmax ) were 2.4-3.0 and 1.5-1.7, respectively. Steady state was achieved by 6-7 days, based on trough observed plasma drug concentration (Ctrough ) values.
Asunto(s)
Indazoles/administración & dosificación , Indoles/administración & dosificación , Oxazoles/administración & dosificación , Piperazinas/administración & dosificación , Inhibidores de Proteínas Quinasas/administración & dosificación , Administración por Inhalación , Adulto , Área Bajo la Curva , Pueblo Asiatico , Método Doble Ciego , Esquema de Medicación , Inhaladores de Polvo Seco , Voluntarios Sanos , Humanos , Indazoles/efectos adversos , Indazoles/sangre , Indazoles/farmacocinética , Indoles/efectos adversos , Indoles/sangre , Indoles/farmacocinética , Masculino , Persona de Mediana Edad , Oxazoles/efectos adversos , Oxazoles/sangre , Oxazoles/farmacocinética , Piperazinas/efectos adversos , Piperazinas/sangre , Piperazinas/farmacocinética , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/sangre , Inhibidores de Proteínas Quinasas/farmacocinéticaRESUMEN
PURPOSE: Novel therapies to treat chronic obstructive pulmonary disease are highly desirable. The safety, tolerability, and pharmacokinetic (PK) parameters of nemiralisib, a phosphoinositide 3-kinase δ inhibitor, administered via the Ellipta dry powder inhaler (GlaxoSmithKline, Research Triangle Park, North Carolina) was evaluated, including an assessment of oral bioavailability. METHODS: This single-center, 3-part, placebo-controlled trial in 22 healthy subjects evaluated single (100 and 200 µg) and repeat (200 µg for 10 days) doses of inhaled nemiralisib in parts A (nâ¯=â¯12) and B (nâ¯=â¯12) (double-blind) and single doses of inhaled nemiralisib (200 µg) with and without charcoal block in Part C (nâ¯=â¯6) (open-label, 2-period, crossover). There was a minimum 14-day washout period between dosing days. FINDINGS: 21 subjects completed the study, mean age was similar in the three parts (A: 49 years; B: 44 years; C: 55 years). After single doses of nemiralisib, observed plasma Cmax dropped rapidly, followed by a slower elimination phase. Near-dose proportionality was observed: mean (95% CI) plasma Cmax and AUC0-24 values were 174.3 pg/mL (96.9-313.3) and 694.6 pg·h/mL (503.5-958.2) for 100 µg and 398.9 pg/mL (318.3-500.1) and 1699.6 pg·h/mL (1273.3-2268.7) for 200 µg, respectively. Repeat dosing for 10 days showed exposures â¼2- to 4-fold higher than on the single dose (peak, trough, and AUC0-24 levels), achieving steady-state by day 6. Mean AUC0-24 was 2193.6 pg·h/mL and 1645.3 pg·h/mL in the absence/presence of charcoal. Two non-drug-related adverse events were observed; neither was serious or resulted in withdrawal. IMPLICATIONS: Inhalation of nemiralisib was well tolerated in these healthy subjects. Plasma pharmacokinetic variables were well defined, and charcoal block data indicate that â¼23% of the total systemic exposure after inhalation from Ellipta was attributable to orally absorbed drug. ClinicalTrials.gov identifier: NCT02691325.
Asunto(s)
Indazoles/farmacología , Indoles/farmacología , Oxazoles/farmacología , Piperazinas/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Administración por Inhalación , Adulto , Anciano , Área Bajo la Curva , Disponibilidad Biológica , Estudios Cruzados , Método Doble Ciego , Inhaladores de Polvo Seco , Femenino , Voluntarios Sanos , Humanos , Indazoles/sangre , Indoles/sangre , Masculino , Persona de Mediana Edad , Oxazoles/sangre , Inhibidores de las Quinasa Fosfoinosítidos-3 , Piperazinas/sangre , Inhibidores de Proteínas Quinasas/sangreRESUMEN
Over the past decade, the prevalence of infections involving methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis (CF) has increased significantly. Tedizolid (TZD) demonstrates excellent activity against MRSA and a favorable safety profile. The pharmacokinetics of several antibiotics have been shown to be altered in CF patients. The purpose of this study was to characterize the pharmacokinetics of tedizolid in this population. Eleven patients with CF were randomized to receive tedizolid phosphate at 200 mg orally or intravenously once daily for 3 doses with a minimum 2-day washout, followed by crossover to the remaining dosage form. Plasma and expectorated sputum were collected following the third dose of each dosage form for analysis. Population pharmacokinetic analysis was performed using the maximum likelihood expectation maximization method, and the disposition of TZD was described by a two-compartment model. The sputum concentrations exceeded the unbound plasma concentrations with an estimated mean sputum-to-unbound plasma penetration ratio of 2.88 (coefficient of variation, 50.3%). The estimated population mean ± standard deviation of total clearance, central volume of distribution, and bioavailability were 9.72 ± 1.62 liters/h, 61.6 ± 6.94 liters, and 1.04 ± 0.232, respectively. The total clearance was higher in CF patients than in healthy volunteers; however, it was similar to published data for patients with complicated skin and skin structure infections (cSSSIs). This study demonstrates that the oral bioavailability of tedizolid is excellent in patients with CF and that the plasma pharmacokinetics are similar to those reported for patients with cSSSIs.
Asunto(s)
Antibacterianos/sangre , Antibacterianos/farmacocinética , Fibrosis Quística/sangre , Fibrosis Quística/microbiología , Organofosfatos/sangre , Organofosfatos/farmacocinética , Oxazoles/sangre , Oxazoles/farmacocinética , Plasma/metabolismo , Administración Intravenosa/métodos , Administración Oral , Adulto , Disponibilidad Biológica , Estudios Cruzados , Femenino , Humanos , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Estudios Prospectivos , Esputo/metabolismoRESUMEN
Parecoxib (PX), a prodrug of valdecoxib (VX), is an injectable selective COX-2 inhibitor, and is recommended for the treatment of cancer pain. PX can be rapidly hydrolyzed into its active metabolite VX, and VX is further metabolized into hydroxylated valdecoxib (OH-VX) by cytochrome P450 enzymes. However, cancer patients have been reported to possess reduced drug metabolism ability, which might cause excessive drug accumulation. Such overdose of PX significantly increased the risk of renal safety and cardiovascular events. Therefore, it is necessary to elucidate the concentration profiles of PX and its metabolites in cancer status. In this study, a sensitive, rapid and specific LC-MS/MS method for quantification of PX, VX and OH-VX in the plasma of tumor bearing mouse was developed and validated. After protein precipitation, all the analytes were separated on an Agilent ZORBAX Extend-C18 HPLC column (2.1â¯×â¯100â¯mm, 3.5⯵m) with gradient elution. The analytes were detected by an electrospray negative ionization mass spectrometry in the multiple reaction monitoring mode. The transition m/z 369.0â¯ââ¯119.0,â¯m/z 312.9â¯ââ¯117.9, m/z 329.0â¯ââ¯196.0, and m/z 307.1â¯ââ¯161.3 were used for monitoring PX, VX, OH-VX and IS respectively. The calibration curves of the analytes showed good linearity over the concentration range of 3-3000â¯ng/mL for PX and VX, and 3-1000â¯ng/mL for OH-VX. Intra- and inter-batch accuracies (in terms of relative error, REâ¯<â¯9.9%) and precisions (in terms of relative standard deviation, RSDâ¯<â¯8.8%) satisfied the standard of validation. The matrix effect, recovery and stability were also within acceptable criteria. The method was successfully applied to the pharmacokinetics study of PX in tumor bearing mice, and PX and VX levels were found elevated with the growth of tumor volume, which might increase the risk of drug overdose.
Asunto(s)
Inhibidores de la Ciclooxigenasa 2/sangre , Monitoreo de Drogas/métodos , Isoxazoles/sangre , Neoplasias/metabolismo , Profármacos/análisis , Animales , Línea Celular Tumoral , Cromatografía Líquida de Alta Presión/instrumentación , Cromatografía Líquida de Alta Presión/métodos , Inhibidores de la Ciclooxigenasa 2/metabolismo , Sistema Enzimático del Citocromo P-450/metabolismo , Monitoreo de Drogas/instrumentación , Femenino , Humanos , Isoxazoles/metabolismo , Isoxazoles/farmacocinética , Ratones , Ratones Endogámicos BALB C , Neoplasias/sangre , Oxazoles/sangre , Oxazoles/metabolismo , Oxazoles/farmacocinética , Profármacos/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray , Sulfonamidas/sangre , Sulfonamidas/metabolismo , Sulfonamidas/farmacocinética , Espectrometría de Masas en Tándem/instrumentación , Espectrometría de Masas en Tándem/métodos , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
(R)-4-((4-(((4-((tetrahydrofuran-3-yl)oxy)benzo[d]isoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol (TBPT), a serotonin-4 receptor partial agonist, is metabolized to two metabolites: an N-dealkylation product [(R)-3-(piperidin-4-ylmethoxy)-4-((tetrahydrofuran-3-yl)oxy)benzo[d]isoxazole (M1)] and a cyclized oxazolidine structure [7-(((4-(((R)-tetrahydrofuran-3-yl)oxy)benzo[d]isoxazol-3-yl)oxy)methyl)octahydro-3H (M2)]. After administration of TBPT to humans the exposure to M1 was low and the exposure to M2 was high, relative to the parent drug, despite this being the opposite in vitro. In this study, projection of the plasma metabolite/parent (M/P) ratios for M1 and M2 was attempted using in vitro metabolism, binding, and permeability data in static and dynamic physiologically based pharmacokinetic (PBPK) models. In the static model, the fraction of parent clearance yielding the metabolite (which also required taking into account secondary metabolites of M1 and M2), the clearance of the metabolites and parent, and an estimate of the availability of the metabolites from the liver were combined to yield estimated parent/metabolite ratios of 0.32 and 23 for M1 and M2, respectively. PBPK modeling that used in vitro and physicochemical data input yielded estimates of 0.26 and 20, respectively. The actual values were 0.12 for M1/TBPT and 58 for M2/TBPT. Thus, the ratio for M1 was overpredicted, albeit at values less than unity. The ratio for M2/TBPT was underpredicted, and the high ratio of 58 may exceed a limiting ceiling of the approach. Nevertheless, when considered in the context of determining whether a potential circulating metabolite may be quantitatively important prior to administration of a drug for the first time to humans, the approaches succeeded in highlighting the importance of M2 (M/P ratio >> 1) relative to M1, despite M1 being much greater than M2 in vitro.
Asunto(s)
Furanos/sangre , Furanos/farmacocinética , Inactivación Metabólica/fisiología , Oxazoles/sangre , Oxazoles/farmacocinética , Agonistas de Receptores de Serotonina/sangre , Agonistas de Receptores de Serotonina/farmacocinética , Adulto , Ciclización/fisiología , Remoción de Radical Alquila/fisiología , Femenino , Hepatocitos/metabolismo , Humanos , Cinética , Masculino , Persona de Mediana Edad , Modelos Biológicos , Adulto JovenRESUMEN
PURPOSE: Tedizolid phosphate is a next-generation oxazolidinone prodrug that is transformed into the active moiety tedizolid. Its indication is acute bacterial skin and skin structure infections caused by gram-positive species, including methicillin-resistant Staphylococcus aureus. Although tedizolid phosphate has been marketed in Korea, no data on the pharmacokinetic (PK) properties or tolerability of tedizolid phosphate in Korean subjects are available. This study was designed to evaluate the PK properties, oral bioavailability, and tolerability with a single-dose oral and intravenous administration of tedizolid phosphate in healthy Korean male subjects. METHODS: A block-randomized, double-blind, placebo-controlled, single-dose study was conducted in 3 groups (200, 400, and 600 mg; 10 subjects in each group). In the second part of the study, subjects from the 200-mg group received administration orally and intravenously (1-hour infusion) via 2-way crossover for the evaluation of absolute bioavailability. There was a 7-day washout period between treatments in the absolute bioavailability part of the study. Serial blood samples for PK analysis were collected for up to 72 hours. Tolerability was assessed by analysis of adverse events. FINDINGS: Thirty healthy Korean subjects completed the study and were included in the PK and tolerability analyses. Tedizolid phosphate was rapidly converted into tedizolid. After a single oral dose, the Tmax of tedizolid was observed to be 1.5 to 2.5 hours, and the plasma concentration-time curve of tedizolid showed a 2-phase elimination pattern, with a half-life of ~11 hours. Dose-dependent increases were observed in the AUClast value (29,441-78,062 µg · h/L) and in the Cmax value (2679-6980 µg/L) with the administration of tedizolid phosphate 200 to 600 mg PO. The absolute bioavailability of tedizolid was 95.2% (90% CI, 92.7%-97.8%) in the 200-mg administration group. There were no serious adverse events or clinically significant changes in the tolerability assessment. IMPLICATIONS: Tedizolid phosphate at doses of up to 600 mg was well-tolerated in these healthy Korean male subjects. Tedizolid shows dose linearity with oral administration, and no dose adjustment of tedizolid phosphate 200 mg would be needed when switching administration routes. ClinicalTrials.gov identifier: NCT02097043.
Asunto(s)
Antibacterianos , Organofosfatos , Oxazoles , Profármacos , Administración Intravenosa , Administración Oral , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antibacterianos/sangre , Antibacterianos/farmacocinética , Disponibilidad Biológica , Estudios Cruzados , Método Doble Ciego , Semivida , Voluntarios Sanos , Humanos , Masculino , Organofosfatos/administración & dosificación , Organofosfatos/efectos adversos , Organofosfatos/sangre , Organofosfatos/farmacocinética , Oxazoles/administración & dosificación , Oxazoles/efectos adversos , Oxazoles/sangre , Oxazoles/farmacocinética , Profármacos/administración & dosificación , Profármacos/efectos adversos , Profármacos/farmacocinética , República de Corea , Adulto JovenRESUMEN
Zolmitriptan is a serotonin (5-HT) 1B/1D receptor agonist effective for the treatment of migraine. This analysis aimed to develop a population pharmacokinetic (PK) model for zolmitriptan and its active metabolite in adults and adolescents and provide appropriate dosing regimens to be used in clinical trials for children 6-11 years old. The data from a single-dose clinical study of 5.0-mg zolmitriptan nasal spray (ZNS) conducted in adult and adolescent patients with migraine between migraine attacks was applied. Similar plasma concentration profiles of zolmitriptan and its metabolite, 183C91, were observed in adults and adolescents. A 1-compartment model with first-order absorption and first-order elimination reasonably described the zolmitriptan PK. With a portion of elimination of zolmitriptan being treated as the conversion from zolmitriptan to 183C91, the disposition of 183C91 was described by a 1-compartment model with first-order elimination. The estimated typical apparent volume of distribution and clearance of zolmitriptan were 136 L and 121 L/h, respectively, with 56.5% and 42.6% between-subject variability, respectively. Based on the simulation results with the final population PK model, a body weight-based dosing scheme of 5.0 and 2.5 mg ZNS in children greater than and less than 50 kg is recommended to achieve exposures similar to those of the adult and adolescent population administered 5.0 mg ZNS. The recommended doses for children to achieve exposure similar to that observed in adults given 2.5 mg ZNS are 2.5 mg (≥50 kg) and 1.0 mg (15-50 kg). These dosing regimens could be used in future clinical trials.
Asunto(s)
Modelos Biológicos , Oxazolidinonas/administración & dosificación , Oxazolidinonas/farmacocinética , Agonistas del Receptor de Serotonina 5-HT1/administración & dosificación , Agonistas del Receptor de Serotonina 5-HT1/farmacocinética , Triptaminas/administración & dosificación , Triptaminas/farmacocinética , Administración Intranasal , Adolescente , Adulto , Peso Corporal , Niño , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/sangre , Trastornos Migrañosos/tratamiento farmacológico , Trastornos Migrañosos/metabolismo , Oxazoles/sangre , Oxazolidinonas/sangre , Oxazolidinonas/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT1/sangre , Agonistas del Receptor de Serotonina 5-HT1/uso terapéutico , Triptaminas/sangre , Triptaminas/uso terapéutico , Adulto JovenRESUMEN
Given that tedizolid exhibits substantial lung penetration, we hypothesize that it could achieve good efficacy against Streptococcus pneumoniae lung infections. We evaluated the pharmacodynamics of tedizolid for treatment of S. pneumoniae lung infections and compared the efficacies of tedizolid human-simulated epithelial lining fluid (ELF) exposures in immunocompetent and neutropenic murine lung infection models. ICR mice were rendered neutropenic via intraperitoneal cyclophosphamide injections and then inoculated intranasally with S. pneumoniae suspensions. Immunocompetent CBA/J mice were inoculated similarly. Single daily tedizolid doses were administered 4 h postinoculation (termed 0 h). Changes in log10 CFU at 24 h compared with 0-h controls were estimated. Ratios of area under the free-drug concentration-time curve to MIC (fAUC0-24/MIC) required to achieve various efficacy endpoints against each isolate were estimated using the Hill equation. Tedizolid doses in neutropenic and immunocompetent mice that mimic the human-simulated ELF exposure were examined. Stasis, 1-log reduction, and 2-log reduction were achieved at fAUC0-24/MIC of 8.96, 24.62, and 48.34, respectively, in immunocompetent mice and 19.21, 48.29, and 103.95, respectively, in neutropenic mice. Tedizolid at 40 mg/kg of body weight/day and 55 mg/kg/day in immunocompetent and neutropenic mice, respectively, resulted in ELF AUC0-24 comparable to that achieved in humans following a 200-mg once-daily clinical dose. These human-simulated ELF exposures were adequate to attain >2-log reduction in bacterial burden at 24 h in 3 out of 4 isolates in both models and 1.58- and 0.74-log reductions with the fourth isolate in immunocompetent and neutropenic mice, respectively. Tedizolid showed potent in vivo efficacy against S. pneumoniae in both immunocompetent and neutropenic lung infection models, which support its consideration for S. pneumoniae lung infections.
Asunto(s)
Antibacterianos/farmacología , Modelos Estadísticos , Neutropenia/tratamiento farmacológico , Organofosfatos/farmacología , Oxazoles/farmacología , Neumonía Neumocócica/tratamiento farmacológico , Streptococcus pneumoniae/efectos de los fármacos , Animales , Antibacterianos/sangre , Antibacterianos/farmacocinética , Área Bajo la Curva , Ciclofosfamida , Modelos Animales de Enfermedad , Esquema de Medicación , Cálculo de Dosificación de Drogas , Humanos , Inmunocompetencia , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/microbiología , Ratones , Ratones Endogámicos CBA , Ratones Endogámicos ICR , Pruebas de Sensibilidad Microbiana , Neutropenia/inducido químicamente , Neutropenia/inmunología , Neutropenia/microbiología , Organofosfatos/sangre , Organofosfatos/farmacocinética , Oxazoles/sangre , Oxazoles/farmacocinética , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/microbiología , Mucosa Respiratoria/efectos de los fármacos , Mucosa Respiratoria/inmunología , Mucosa Respiratoria/microbiología , Streptococcus pneumoniae/crecimiento & desarrolloRESUMEN
4,4'-DMAR is an analogue of the known psychostimulants 4-methylaminorex and aminorex. In the light of reports of deaths associated with its abuse, and the easy access from Internet vendors, the EU Council recently decided on control measures across member states. Here we describe a validated method for measuring plasma levels of cis-4,4'-DMAR, crucial for preclinical studies and analysis in human plasma. Chromatographic separation was done by gradient elution on a Kinetex C18 column with 0.1% formic acid in water and 0.1% formic acid in acetonitrile at 0.2 mL/min. Detection was by positive electrospray ionization (ESI+) in multiple reaction monitoring mode monitoring the quantifier transitions m/z 191.4 â m/z 148.3 for cis-4,4'-DMAR and m/z 259.3 â m/z 194.2 for carbamazepine (internal standard). Protein precipitation with 1% of formic acid in acetonitrile was used in cis-4,4'-DMAR extraction from plasma; recovery was high (>93%) with a negligible matrix effect. This method provides an accurate, precise, and sensitive method for cis-4,4'-DMAR quantification in human and rat plasma, following European Medicine Agency guidelines for bioanalytical method validation. Pharmacokinetic studies were conducted in rats. After an intravenous dose of 1 mg/kg, plasma levels declined rapidly (≥80% in 4 h), followed by a slow elimination phase (t1/2 of 5.14 ± 0.65 h). Absorption was rapid after intraperitoneal injection (tmax = 15 min) with a rapid decline thereafter; Cmax and AUC0-240min showed dose-proportionality over the dose range 1-10 mg/kg. This method was successfully applied to investigate pharmacokinetic properties in rats and could be used to quantify cis-4,4'-DMAR levels in human plasma. Copyright © 2016 John Wiley & Sons, Ltd.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Drogas Ilícitas/sangre , Oxazoles/sangre , Psicotrópicos/sangre , Espectrometría de Masas en Tándem/métodos , Animales , Humanos , Límite de Detección , Masculino , Ratas , Ratas Wistar , Detección de Abuso de Sustancias/métodosRESUMEN
A sensitive and specific UPLC-MS/MS method was developed and validated for the simultaneous determination of 2-amino-2-(2-(4'-(2-propyloxazol-4-yl)-[1,1'-biphenyl]-4-yl)ethyl)propane-1,3-diol (SYL930), phosphorylated metabolite (SYL930-P) and hydroxylated metabolite (SYL930-M) in dog blood using SYL927 and SYL927-P, analogues of SYL930, as the internal standards. Analytes were extracted with protein precipitation followed by chromatographic separation on a ZorbaxSB-C18 column (3.5 µm, 2.1 × 100 mm) with a gradient elution of methanol-water containing 0.1% formic acid (v/v). A triple quadrupole tandem mass spectrometer operating in the positive electrospray ionization mode was used to detect SYL930, SYL930-P, SYL930-M and IS transitions of 381.2 â 364.2, 461.2 â 334.2, 397.3 â 380.3, 367.1 â 350.4 and 447.5 â 320.2, respectively. The linear calibration curves for SYL930, SYL930-P and SYL930-M were 0.5-500, 0.2-100 and 0.5-100 ng/mL, respectively (r2 > 0.99). The intra-day and inter-day precisions (RSD, %) of analytes did not exceed 9.16% except for low QCs (≤16.22%), and the accuracy (RE, %) ranged from -14 to 11.4%. The mean recoveries for SYL930, SYL930-P and SYL930-M in dog blood were 85.13-107.94, 73.84-80.08 and 85.64-95.44%, respectively. The validated method was successfully applied to pharmacokinetic and PK/PD studies of SYL930 and its two major metabolites in dogs after an oral administration of SYL930.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Oxazoles/sangre , Oxazoles/metabolismo , Propanolaminas/sangre , Propanolaminas/metabolismo , Espectrometría de Masas en Tándem/métodos , Administración Oral , Animales , Perros , Humanos , Hidroxilación , Oxazoles/administración & dosificación , Fosforilación , Propanolaminas/administración & dosificación , Receptores de Lisoesfingolípidos/antagonistas & inhibidores , Espectrometría de Masa por Ionización de Electrospray/métodos , Receptores de Esfingosina-1-FosfatoRESUMEN
We compared tedizolid alone and tedizolid with rifampin to rifampin and vancomycin plus rifampin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA) foreign body-associated osteomyelitis. The study strain was a prosthetic joint infection-associated isolate. Steady-state pharmacokinetics for intraperitoneal administration of tedizolid, vancomycin, and rifampin were determined in uninfected rats. MRSA was inoculated into the proximal tibia, and a wire was implanted. Four weeks later, the rats were treated intraperitoneally for 21 days with tedizolid (n = 14), tedizolid plus rifampin (n = 11), rifampin (n = 16), or vancomycin plus rifampin (n = 13). Seventeen rats received no treatment. After treatment, quantitative bone cultures were performed. Blood was obtained for determination of drug trough concentrations in the tedizolid and tedizolid plus rifampin groups. The mean peak plasma concentration and mean area under the concentration-time curve from time zero to 24 h for tedizolid were 12 µg/ml and 60 µg · h/ml, respectively. The bacterial loads in all treatment groups were significantly lower than those in the control group; those in the tedizolid- plus rifampin-treated animals were not significantly different from those in the vancomycin- plus rifampin-treated animals. The range of mean plasma trough concentrations in the tedizolid group was 0.44 to 0.73 µg/ml. Although neither tedizolid nor vancomycin resistance was detected in isolates recovered from bones, rifampin resistance was detected in 10 animals (63%) in the rifampin group, 8 animals (73%) in the tedizolid plus rifampin group, and a single animal (8%) in the vancomycin plus rifampin group. Tedizolid alone or tedizolid combined with rifampin was active in a rat model of MRSA foreign body-associated osteomyelitis. The emergence of rifampin resistance was noted in animals receiving tedizolid plus rifampin.
Asunto(s)
Antibacterianos/farmacocinética , Cuerpos Extraños/tratamiento farmacológico , Organofosfatos/farmacocinética , Osteomielitis/tratamiento farmacológico , Oxazoles/farmacocinética , Rifampin/farmacocinética , Infecciones Estafilocócicas/tratamiento farmacológico , Vancomicina/farmacocinética , Animales , Antibacterianos/sangre , Carga Bacteriana/efectos de los fármacos , Hilos Ortopédicos , Modelos Animales de Enfermedad , Combinación de Medicamentos , Farmacorresistencia Bacteriana , Cuerpos Extraños/microbiología , Cuerpos Extraños/patología , Inyecciones Intraperitoneales , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Staphylococcus aureus Resistente a Meticilina/patogenicidad , Pruebas de Sensibilidad Microbiana , Organofosfatos/sangre , Osteomielitis/microbiología , Osteomielitis/patología , Oxazoles/sangre , Ratas , Ratas Wistar , Rifampin/sangre , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/patología , Tibia/efectos de los fármacos , Tibia/lesiones , Tibia/microbiología , Vancomicina/sangreRESUMEN
Gout is a common metabolic disorder caused by the deposition of monosodium urate crystals within joints. A new kind of xanthine oxidase inhibitor, WSJ-537, was developed as a potential drug. In order to investigate the pharmacokinetic behavior in vivo, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination the concentration of WSJ-537 in rat plasma was developed. After extraction by protein precipitation method with acetonitrile, the chromatographic separation was accomplished on a Venusil ASB C18 column(2.1mm×50mm, 3mm)at a flow rate of 0.3mLmin(-1) with the mobile phase consisting of acetonitrile-ammonium acetate (33:67, v/v). An electrospray ionization (ESI) source was applied and operated in the positive ion mode. The plasma concentration was detected by multiple reactions monitoring (MRM) mode with the target fragment ions m/z 410.2âm/z 368.1 for WSJ-537 and m/z 244.1âm/z 185.0 for the IS. Good linearity was observed in the range of 20-800ngmL(-1) (r=0.9947). The recovery of WSJ-537 in rats plasma was more than 85%. This method was suitable for pharmacokinetic studies after oral administration of 10mg/kg WSJ-537 in rats.